Phaseline

Targets › OPRL1

OPRL1 (Nociceptin receptor): drug programs, companies and trials

2 programs from 2 companies in 3 trials: 2 Phase 2, 1 Phase 3; Psychiatry, Other; next expected readout Jan 2027.

G protein-coupled opioid receptor that functions as a receptor for the endogenous neuropeptide nociceptin. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. (UniProt, P41146)

Open in Phaseline: the race on OPRL1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Adneuris TherapeuticsCebranopadol
Nociceptin receptor agonist; Opioid receptors; mu/kappa/delta agonist
OPRL1, OPRK1, OPRD1, OPRM1Phase 3Pain; Chronic PainJan 2027
Mclean HospitalNociceptin Receptor Antagonist (BTRX-246040)
Nociceptin receptor antagonist
OPRL1Phase 2Depressive Disorder, MajorMar 2027

Conditions

Depressive Disorder, Major (1) Pain (1) Chronic Pain (1)

Modalities

small molecule (2)

Companies

Mclean Hospital (1) Adneuris Therapeutics (1)

Related targets

OPRK1 (1) OPRD1 (1) OPRM1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.